Alprazolam for essential tremor

Bruno, Elisa; Quattrocchi, Graziella; Filippini, Graziella; Zappia, Mario; Colosimo, Carlo

doi:10.1002/14651858.cd009681.pub2

Cited by 8 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Italian Movement Disorders Association recommended alprazolam as second-line therapy [ 44 ], and the MDS Task Force on Tremor considered this drug as efficacious [ 13 ]. In contrast, the evidence-based guidelines for the treatment of ET by the American Academy of Neurology [ 43 ], and a systematic review of the literature [ 146 ] concluded that the evidence is not sufficient to support or refute the use of alprazolam in the treatment of ET. Recommended doses of alprazolam blockers are given in Table 5 .…”

Section: Benzodiazepinesmentioning

confidence: 99%

Current and Future Neuropharmacological Options for the Treatment of Essential Tremor

Alonso‐Navarro

García‐Martín

Agúndez

et al. 2020

View full text Add to dashboard Cite

Background: Essential Tremor (ET) is likely the most frequent movement disorder. In this review, we have summarized the current pharmacological options for the treatment of this disorder and discussed several future options derived from drugs tested in experimental models of ET or from neuropathological data. Methods: A literature search was performed on the pharmacology of essential tremors using PubMed Database from 1966 to July 31, 2019. Results: To date, the beta-blocker propranolol and the antiepileptic drug primidone are the drugs that have shown higher efficacy in the treatment of ET. Other drugs tested in ET patients have shown different degrees of efficacy or have not been useful. Conclusion: Injections of botulinum toxin A could be useful in the treatment of some patients with ET refractory to pharmacotherapy. According to recent neurochemical data, drugs acting on the extrasynaptic GABAA receptors, the glutamatergic system or LINGO-1 could be interesting therapeutic options in the future.

show abstract

Section: Benzodiazepinesmentioning

confidence: 99%

Current and Future Neuropharmacological Options for the Treatment of Essential Tremor

Alonso‐Navarro

García‐Martín

Agúndez

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This is in line with the reported adverse events of benzodiazepine, which are due to the anticholinergic effect of benzodiazepine. 16 Among the antipsychotics used in our study, daily doses of levomepromazine maleate, olanzapine, quetiapine and zotepine in 2021 were significant factors associated with the initiation of laxative use. This is in line with a previous study showing that zotepine, quetiapine and olanzapine had the highest rates of laxative use in SGA, followed by clozapine, 9 and levomepromazine maleate was associated with severe constipation.…”

Section: Discussionmentioning

confidence: 62%

Factors associated with the initiation of laxative use in the same patients with schizophrenia over a 20‐year period: Retrospective cohort study

Kawamata,

Sugawara,

Sasaki

et al. 2023

Neuropsychopharm Rep

View full text Add to dashboard Cite

BackgroundConstipation is a common adverse effect of antipsychotics, but little investigation has been conducted. We aimed to address the factors associated with the initiation of laxative use in the same patients with schizophrenia over a 20‐year period.MethodsWe enrolled patients with schizophrenia attending each hospital (n = 14) from April 1, 2021, and retrospectively examined all prescriptions as of April 1, 2016, 2011, 2006, and 2001, every 5 years starting in 2021, for this population. 716 participants with complete data were included in the analysis. The Cochran Q test followed by Bonferroni correction and the Cochran–Armitage trend test were used to determine the differences and trends of the frequency of each laxative. Multivariate logistic regression analysis was performed to assess the factors on the initiation of laxative use over a 20‐year period.ResultsOf the patients, 25.1% were treated with laxatives in 2001, and 34.1% were treated in 2021. The numbers of patients treated with any laxatives significantly differed over the 20‐year period, with a significant increasing trend. In all laxatives, the numbers of patients treated with magnesium oxide, lubiprostone and elobixibat differed with a significant increasing trend. Female sex, age, the total DZP equivalent dose, and the doses of levomepromazine maleate, olanzapine, quetiapine, zotepine, lithium, and carbamazepine in 2021 were significant factors associated with the initiation of laxative use over the 20‐year period.ConclusionsCareful monitoring is needed for patients treated with levomepromazine maleate, olanzapine, quetiapine and zotepine. Optimizing prescriptions according to treatment guidelines could reduce antipsychotic‐induced constipation.

show abstract

“…First line of treatment for ET is pharmacological although even well-established treatments can be ineffective in 25–55% of patients and are often associated with serious adverse events in a large percentage of patients ( 9 ). Pharmacological agents can lose their efficacy over the course of long-term therapy and in cases where the condition is medically refractory, neurosurgery such as radiofrequency (RF) ablation thalamotomy and deep brain stimulation (DBS) is considered.…”

Section: Introductionmentioning

confidence: 99%

‘Am I fixed, am I better now?’: undergoing MR-guided focused ultrasound for essential tremor: an interpretative phenomenological analysis

Stoycheva,

Jameel,

Bain

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

IntroductionEssential tremor (ET) is characterised by postural and intentional tremor typically affecting the upper limbs, which can negatively impact functionality and quality of life. Magnetic Resonance-guided Focused Ultrasound (MRgFUS) is a novel and promising non-invasive treatment for ET which offers instantaneous results.MethodsUsing interpretative phenomenological analysis we explored the experience of undergoing MRgFUS in six ET patients as well as their experiences pre- and post-procedure.ResultsOne-time, retrospective semi-structured interviews were conducted and six themes emerged: Life pre-treatment: “It’s everyday tasks that get you down” and “Most people who understand, they are okay. Some people aren’t”; MRgFUS: Treatment day: “Going into the unknown” and “There’s no way I was going to press that button”; and Life post-treatment: “One is good. Two is better” and “Am I fixed, am I better now?.”DiscussionThe findings point to a significant period of adjustment associated with living with ET and the effects of undergoing ET MRgFUS treatment. As ET progressed, participants struggled to cope with increasing symptoms and had to develop coping strategies to manage life with ET. The procedure itself was perceived as strange and extraordinary and despite some immediate adverse effects participants were determined to go through with it. Post procedure, all participants reported tremor suppression which was life changing. While some participants still felt burdened by ET, others expressed it took them a while to psychologically adjust to what essentially was their new body. This study has highlighted the need for patients to be supported at all stages of their ET journey.

show abstract

Alprazolam for essential tremor

Cited by 8 publications

References 31 publications

Current and Future Neuropharmacological Options for the Treatment of Essential Tremor

Current and Future Neuropharmacological Options for the Treatment of Essential Tremor

Factors associated with the initiation of laxative use in the same patients with schizophrenia over a 20‐year period: Retrospective cohort study

‘Am I fixed, am I better now?’: undergoing MR-guided focused ultrasound for essential tremor: an interpretative phenomenological analysis

Contact Info

Product

Resources

About